List of Levothyroxine Sodium drug patents

Levothyroxine Sodium is owned by Fresenius Kabi Usa.

Levothyroxine Sodium contains Levothyroxine Sodium.

Levothyroxine Sodium has a total of 6 drug patents out of which 0 drug patents have expired.

Levothyroxine Sodium was authorised for market use on 24 June, 2011.

Levothyroxine Sodium is available in powder;intravenous dosage forms.

The generics of Levothyroxine Sodium are possible to be released after 01 December, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168239 FRESENIUS KABI USA Levothyroxine formulations
Aug, 2032

(9 years from now)

US9168238 FRESENIUS KABI USA Levothyroxine formulations
Aug, 2032

(9 years from now)

US9006289 FRESENIUS KABI USA Levothyroxine formulations
Oct, 2032

(9 years from now)

US11135190 FRESENIUS KABI USA Levothyroxine liquid formulations
Dec, 2036

(13 years from now)

US9782376 FRESENIUS KABI USA Levothyroxine liquid formulations
Dec, 2036

(13 years from now)

US10398669 FRESENIUS KABI USA Levothyroxine liquid formulations
Dec, 2036

(13 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 24 June, 2011

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of LEVOTHYROXINE SODIUM before it's patent expiration?
More Information on Dosage

Levothyroxine Sodium is owned by Custopharm Inc.

Levothyroxine Sodium contains Levothyroxine Sodium.

Levothyroxine Sodium has a total of 1 drug patent out of which 0 drug patents have expired.

Levothyroxine Sodium was authorised for market use on 17 May, 2021.

Levothyroxine Sodium is available in solution;intravenous dosage forms.

The generics of Levothyroxine Sodium are possible to be released after 20 July, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154498 CUSTOPHARM INC Stabilized liquid formulation of levothyroxine
Jul, 2036

(13 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 17 May, 2021

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of LEVOTHYROXINE SODIUM before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in